trending Market Intelligence /marketintelligence/en/news-insights/trending/mbwvrfopulz8vsaf7mjxbg2 content esgSubNav
In This List

Sanofi secures antitrust clearance for $11.6B acquisition of Bioverativ

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Sanofi secures antitrust clearance for $11.6B acquisition of Bioverativ

French drugmaker Sanofi secured U.S. antitrust clearance for its $11.6 billion acquisition of Waltham, Mass.-based hemophilia specialist Bioverativ Inc.

The waiting period under the Hart-Scott-Rodino Act related to the deal has expired, which means the transaction has received antitrust clearance.

The acquisition is still subject to other conditions, including the tender of at least a majority of Bioverativ's common stock.

On Feb. 7, Sanofi started a tender offer to buy all of Bioverativ's outstanding shares for $105 apiece in cash. The offer will expire March 7.